Burchert et al. found that IFN-α therapy was associated with an increased expression of leukemia-associated antigen proteinase-3 suggesting that the induction of proteinase-3-specific CTLs may contribute to sustained remission after Imatinib discontinuation [176]. Here, PRTN3 is linked to leukemia.